Wire · opportunities
Arrowhead's Ionis problem, Kyverna's next-gen end and more biotech earnings
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 November 2026 · Fusion42 review
Ionis Pharmaceuticals' Tryngolza significantly underperformed sales expectations in the severe hypertriglyceridemia (sHTG) market, causing concern for Arrowhead Pharmaceuticals as they prepare to launch Redemplo in the same indication. Arrowhead has submitted Redemplo for FDA review under the accelerated STAR pilot program aiming for faster approval.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a tougher market than expected for triglyceride drugs after Ionis’s weak Tryngolza sales. Launching Redemplo under the FDA’s accelerated program is your potential edge this quarter.
◆ Coverage
1 source · 13 Nov 2026
◆ Related on Wire
◆ Topics